Hyponatremia is often associated with arginine vasopressin (AVP) dysregulation that is regulated by the hypothalamo-neurohypophyseal tract in response to changes in plasma osmolality, commonly in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Potentially lethal complications of hyponatremia most frequently involve the central nervous system and include anorexia, fatigue, lethargy, delirium, seizures, hypothermia and coma, and require prompt treatment. Chronic hyponatremia also complicates patient care and is associated with increased morbidity and mortality, particularly among patients with congestive heart failure. Conventional treatments for hyponatremia (e.g. fluid restriction, diuretic treatment, and sodium replacement) may not be effective in all patients and can lead to significant adverse events. Preclinical and clinical trial results have shown that AVP receptor antagonism is a promising approach to the treatment of hyponatremia that directly addresses the effects of increased AVP and consequent decreased aquaresis, the electrolyte-sparing excretion of free water. Agents that antagonize V2 receptors promote aquaresis and can lead to increased serum sodium. Dual-receptor antagonism, in which both V2 and V1A receptors are blocked, may provide additional benefits in patients with hyponatremia.

Keywords:
Aquaporins, Arginine vasopressin, Vasopressin-receptor antagonist, SIADH, Hyponatremia, vasopressin dysregulation
1.
Nielsen S, Frokiaer J, Marples, et al: Aquaporins in the kidney: from molecules to medicine. Physiol Rev 2002;82:205–244.
2.
Bertuccio CA, Ibarra FR, Toledo JE, et al: Endogenous vasopressin regulates Na-K-ATPase and Na+-K+-Cl cotransporter rbsc-1 in rat outer medulla. Am J Physiol Renal Physiol 2002;282:F265–F270.
3.
Gross P, Wehrle R, Bussemaker E: Hyponatremia: pathophysiology, differential diagnosis and new aspects of treatment. Clin Nephrol 1996;46:273–276.
4.
Goh KP: Management of hyponatremia. Am Fam Physician 2004;69:2387–2394.
5.
Adrogue HJ, Madias NE: Hyponatremia. N Engl J Med 2000;342:1581–1589.
6.
Miller M: Syndromes of excess antidiuretic hormone release. Crit Care Clin 2001;17:11–23.
7.
Baylis PH: The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol 2003;35:1495–1499.
8.
Wong LL, Verbalis JG: Vasopressin V2 receptor antagonists. Cardiovasc Res 2001;51:391–402.
9.
Han DS, Cho BS: Therapeutic approach to hyponatremia. Nephron 2002;92(suppl 1):9–13.
10.
Flear CT, Gill GV, Burn J: Hyponatraemia: mechanisms and management. Lancet 1981;2:26–31.
11.
Natkunam A, Shek CC, Swaminathan R: Hyponatremia in a hospital population. J Med 1991;22:83–96.
12.
DeVita MV, Gardenswartz MH, Konecky A, Zabetakis PM: Incidence and etiology of hyponatremia in an intensive care unit. Clin Nephrol 1990;34:163–166.
13.
Anderson RJ, Chung HM, Kluge R, Schrier RW: Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985;102:164–168.
14.
Amede FJ, James KA, Michelis MF, Gleim GW: Changes in serum sodium, sodium balance, water balance, and plasma hormone levels as the result of pelvic surgery in women. Int Urol Nephrol 2002;34:545–550.
15.
Amini A, Schmidt MH: Syndrome of inappropriate secretion of antidiuretic hormone and hyponatremia after spinal surgery. Neurosurg Focus 2004;16:E10.
16.
Casulari LA, Costa KN, Albuquerque RC, et al: Differential diagnosis and treatment of hyponatremia following pituitary surgery. J Neurosurg Sci 2004;48:11–18.
17.
Miller M, Morley JE, Rubenstein LZ: Hyponatremia in a nursing home population. J Am Geriatr Soc 1995;43:1410–1413.
18.
Sonnenblick M, Friedlander Y, Rosin AJ: Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest 1993;103:601–606.
19.
Lee CT, Guo HR, Chen JB: Hyponatremia in the emergency department. Am J Emerg Med 200;18:264–268.
20.
Terzian C, Frye EB, Piotrowski ZH: Admission hyponatremia in the elderly: factors influencing prognosis. J Gen Intern Med 1994;9:89–91.
21.
Chen MC, Chang HW, Cheng CI, et al: Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy. Cardiology 2003;100:136–142.
22.
Lee WH, Packer M: Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986;73:257–267.
23.
Borroni G, Maggi A, Sangiovanni A, et al: Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Dig Liver Dis 2000;32:605–610.
24.
Fried LF, Palevsky PM: Hyponatremia and hypernatremia. Med Clin North Am 1997;81:585–609.
25.
Kumar S, Berl T: Sodium. Lancet 1998;352:220–228.
26.
Decaux G, Soupart A: Treatment of symptomatic hyponatremia. Am J Med Sci 2003;326:25–30.
27.
Lin SH, Hsu YJ, Chiu JS, et al: Osmotic demyelination syndrome: a potentially avoidable disaster. QJM 2003;96:935–947.
28.
Verbalis JG: Vasopressin V2 receptor antagonists. J Mol Endocrinol 2002;29:1–9.
29.
Ishikawa SE, Schrier RW: Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol 2003;58:1–17.
30.
Robertson GL: Antidiuretic hormone. Normal and disordered function. Endocrinol Metab Clin North Am 2001;30:671–694.
31.
Lee CR, Watkins ML, Patterson JH, et al: Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003;146:9–18.
32.
Ferguson JW, Therapondos G, Newby DE, Hayes PC: Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci 2003;105:1–8.
33.
Thibonnier M, Coles P, Thibonnier A, Shoham M: The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 2001;41:175–202.
34.
Gheorghiade M, Gattis WA, Barbagelata A, et al: Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J 2003;145(suppl 2):S51–S54.
35.
Goldsmith SR: Vasopressin: a therapeutic target in congestive heart failure? J Card Fail 1999;5:347–356.
36.
Nielsen S: Renal aquaporins: an overview. BJU Int 2002;90(suppl 3):1–6.
37.
Tian Y, Sandberg K, Murase T, et al: Vasopressin V2 receptor binding is down-regulated during renal escape from vasopressin-induced antidiuresis. Endocrinology 2000;141:307–314.
38.
Ecelbarger CA, Chou CL, Lee AJ, et al: Escape from vasopressin-induced antidiuresis: role of vasopressin resistance of the collecting duct. Am J Physiol 1998;274:F1161–F1166.
39.
Bartter FC, Schwartz WB: The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1967;42:790–806.
40.
Kovacs L, Robertson GL: Syndrome of inappropriate antidiuresis. Endocrinol Metab Clin North Am 1992;21:859–875.
41.
Kinzie BJ: Management of the syndrome of inappropriate secretion of antidiuretic hormone. Clin Pharm 1987;6:625–633.
42.
Oh MS: Pathogenesis and diagnosis of hyponatremia. Nephron 2002;92(suppl):2–8.
43.
Harrigan MR: Cerebral salt wasting syndrome. Crit Care Clin 2001;17:125–138.
44.
Chung HM, Kluge R, Schrier RW, et al: Postoperative hyponatremia. A prospective study. Arch Intern Med 1986;146:333–336.
45.
Bouman WP, Pinner G, Johnson H: Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int J Geriatr Psychiatry 1998;13:12–15.
46.
Fabian TJ, Amico JA, Kroboth PD, et al: Paroxetine-induced hyponatremia in the elderly due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Geriatr Psychiatry Neurol 2003;16:160–164.
47.
Fabian TJ, Amico JA, Kroboth PD, et al: Paroxetine induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med 2004;164:327–332.
48.
Rosner MH: Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors. Am J Med Sci 2004;327:109–111.
49.
Kugler JP, Hustead T: Hyponatremia and hypernatremia in the elderly. Am Fam Physician 2000;61:3623–3630.
50.
Ayus JC, Arieff AI: Abnormalities of water metabolism in the elderly. Semin Nephrol 1996;16:277–288.
51.
Phillips PA, Rolls BJ, Ledingham JG, et al: Reduced thirst after water deprivation in healthy elderly men. N Engl J Med 1984;311:753–759.
52.
Ledingham JG, Crowe MJ, Forsling ML, et al: Effects of aging on vasopressin secretion, water excretion, and thirst in man. Kidney Int Suppl 1987;21:S90–S92.
53.
Creager MA, Faxon DP, Cutler SS, et al: Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 1986;7:758–765.
54.
Schrier RW, Fassett RG: Pathogenesis of sodium and water retention in cardiac failure. Ren Fail 1998;20:773–781.
55.
Kalra PR, Anker SD, Coats AJ: Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc Res 2001;51:495–509.
56.
Goldsmith SR, Gheorghiade M: Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005;46:1785–1791.
57.
Goldsmith SR: Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. J Am Coll Cardiol 2005;95:14B–23B.
58.
Lee DS, Austin PC, Rouleau JL, et al: Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290:2581–2587.
59.
Gines P, Berl T, Bernardi M, Bichet DG: Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998;28:851–864.
60.
Gerbes AL, Gulberg V: Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933–939.
61.
Palm C, Gross P: V2-vasopressin receptor antagonists-mechanism of effect and clinical implications in hyponatraemia. Nephrol Dial Transplant 1999;14:2559–2562.
62.
Palm C, Reimann D, Gross P: The role of V2 vasopressin antagonists in hyponatremia. Cardiovasc Res 2001;51:403–408.
63.
Andreoli TE: Water: normal balance, hyponatremia, and hypernatremia. Ren Fail 2000;22:711–735.
64.
Ohnishi A, Orita Y, Okahara R, et al: Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993;92:2653–2659.
65.
Ohnishi A, Orita Y, Takagi N, et al: Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J Pharmacol Exp Ther 1995;272:546–551.
66.
Burrell LM, Phillips PA, Risvanis J, et al: Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am J Physiol 1998;275:H176–H182.
67.
Burrell LM, Risvanis J, Johnston CI, et al: Vasopressin receptor antagonism-a therapeutic option in heart failure and hypertension. Exp Physiol 2000;85:259S–265S.
68.
Udelson JE, Smith WB, Hendrix GH, et al: Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417–2423.
69.
Serradeil-Le Gal C, Wagnon J, Valette G, et al: Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1A, V2 and V1B receptor ligands. Prog Brain Res 2002;139:197–210.
70.
Goldsmith SR: Vasopressin antagonists in CHF: ready for clinical trials? Cardiovasc Res 2002;54:13–15.
71.
Decaux G: Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 2001;138:18–21.
72.
Wong F, Blei AT, Blendis LM, Thuluvath PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182–191.
73.
Gheorghiade M, Niazi I, Ouyang J, et al: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690–2696.
74.
Gheorghiade M, Gattis WA, O’Connor CM, et al: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963–1971.
75.
Saito T, Ishikawa S, Abe K, et al: Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 1997;82:1054–1057.
76.
Inoue T, Ohnishi A, Matsuo A, et al: Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998;63:561–570.
77.
Martinez-Castelao A: Conivaptan (Yamanouchi). Curr Opin Investig Drugs 2002;3:89–95.
78.
Burnier M, Fricker AF, Hayoz D, et al: Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 1999;55:633–637.
79.
Abraham WT, Suresh DP, Wagoner LE, et al: Pharmacotherapy for hyponatremia in heart failure: effects of a dual V1A/V2 vasopressin antagonist YM087 (abstract 1562). Circulation 1999;100(suppl):I-299.
80.
Abraham W, Suresh DP, Wagoner LE, et al: Pharmacotherapy for hyponatremia in heart failure: effects of a new combined vasopressin V1A/V2 receptor antagonist, conivaptan (YM087) administered orally (abstract 1849). Eur Heart J 2000;21:345.
81.
Abraham W, Koren M, Bichet DG, et al: Treatment of hyponatremia in patients with SIADH or CHF with intravenous conivaptan (YM087), a new combined vasopressin V1A/V2 receptor antagonist (abstract 1848). Eur Heart J 2000;21:345.
82.
Bichet DG, Madore F, Cusson J, et al: Pharmacotherapy for hyponatremia in SIADH: effects of a new orally administered V1A/V2 antagonist YM087 (abstract A0613). J Am Soc Nephrol. 1999;10:119A.
83.
Verbalis JG, Bisaha J, Smith N: Novel vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration and effective water clearance in a hyponatremia clinical trial (abstract SA-P0254). J Am Soc Nephrol 2004;15:356A.
84.
Gross P, Bisaha J, Smith N: Conivaptan, a novel V1A/V2 antagonist, increased serum sodium and effective water clearance in a hyponatremia clinical trial. (abstract SA-P2043). J Am Soc Nephrol 2004;15:353A.
85.
Ghali JK, Bisaha J, Smith N: Efficacy of the vasopressin V1A/V2 antagonist conivaptan in a clinical trial of euvolemic or hypervolemic hyponatremia (abstract SA-P0252). J Am Soc Nephrol 2004;15:355A.
© 2006 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.